↓ Skip to main content

Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (55th percentile)

Mentioned by

patent
5 patents

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
26 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics
Published in
Journal for Immunotherapy of Cancer, November 2015
DOI 10.1186/2051-1426-3-s2-o9
Authors

Christopher Harvey, Kutlu Elpek, Ellen Duong, Tyler Simpson, ChengYi J Shu, Lindsey Shallberg, Matthew Wallace, Sriram Sathyanarayanan, Robert Mabry, Michael Briskin, Jennifer Michaelson, Thomas F Gajewski

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Australia 1 4%
Unknown 25 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 46%
Student > Doctoral Student 3 12%
Student > Master 2 8%
Student > Ph. D. Student 2 8%
Lecturer 1 4%
Other 3 12%
Unknown 3 12%
Readers by discipline Count As %
Immunology and Microbiology 5 19%
Biochemistry, Genetics and Molecular Biology 4 15%
Agricultural and Biological Sciences 4 15%
Medicine and Dentistry 3 12%
Pharmacology, Toxicology and Pharmaceutical Science 2 8%
Other 2 8%
Unknown 6 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 December 2021.
All research outputs
#8,535,472
of 25,374,917 outputs
Outputs from Journal for Immunotherapy of Cancer
#2,057
of 3,421 outputs
Outputs of similar age
#102,287
of 296,797 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#38
of 98 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,421 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 296,797 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.